EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Precision BioSciences EBITDA Margin % Related Terms
Precision BioSciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Precision BioSciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PBS0 vs TLSA, EQ, MIST: EBITDA Margin % Comparison
For the Biotechnology subindustry, Precision BioSciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precision BioSciences EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Precision BioSciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Precision BioSciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precision BioSciences (STU:PBS0) has a EBITDA Margin % of -161.38% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Precision BioSciences and its competitors. According to the industry distribution chart, Precision BioSciences ranks #494 out of 943 companies in the Biotechnology industry, placing it in the top 52.4%.
Is Precision BioSciences' EBITDA Margin % too high?
Precision BioSciences' current EBITDA Margin % is -161.38%. Based on the distribution chart, Precision BioSciences ranks #494 out of 943 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Precision BioSciences has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Precision BioSciences' EBITDA Margin % compare to TLSA and EQ?
According to the Biotechnology industry distribution chart, Precision BioSciences ranks #494 out of 943 companies for EBITDA Margin %. This places Precision BioSciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Precision BioSciences and its competitors. Precision BioSciences's current EBITDA Margin % is -161.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precision BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Precision BioSciences (STU:PBS0) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.52, compared to a current price of €6.06 — trading 298.7% above its estimated fair value. The current EBITDA Margin % is -161.38%. Precision BioSciences' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Precision BioSciences (STU:PBS0), the current EBITDA Margin % is -161.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precision BioSciences (STU:PBS0) Overvalued in 2026?
Based on GuruFocus' analysis, Precision BioSciences stock appears to be overvalued.
The current stock price of €6.06 is trading 298.7% above its estimated GF Value™ of €1.52.
GuruFocus considers Precision BioSciences to be Significantly Overvalued.
Key valuation signals for STU:PBS0:
EBITDA Margin %: -161.38%
GF Value™: €1.52 vs. price of €6.06 (298.7% above fair value)
No single metric tells the full story. See the STU:PBS0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
48GF Score
Get the complete analysis for STU:PBS0
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PBS0 has been successfully added to your 
